The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 1,394,121 | 1,788,948 | 1,966,742 | 3,533,134 |
| Interest earned on cash held in trust account | 1,850,659 | 2,044,444 | 6,440,067 | - |
| Change in fair value of over-allotment liability | - | 0 | - | - |
| Payment of operating costs through promissory note | - | 0 | 0 | - |
| Prepaid expenses | 25,992 | -38,757 | -23,750 | -25,498 |
| Long-term prepaid insurance | 0 | 0 | -37,758 | -75,517 |
| Accounts payable and accrued expenses | 249,496 | 87,863 | 32,553 | -153,961 |
| Accrued offering costs | 0 | -90,000 | -89,984 | - |
| Due to related party | 75,000 | 75,000 | 75,000 | 635,857 |
| Accrued expenses | - | - | - | -89,984 |
| Dividend income earned on marketable securities held in trust account | - | - | - | 4,247,746 |
| Net cash used in operating activities | -158,035 | -143,876 | -56,518 | -221,685 |
| Investment of cash in trust account | - | 0 | - | - |
| Cash withdrawn from trust account for allowable working capital purposes | - | 250,000 | 0 | 250,000 |
| Net cash provided by investing activities | - | 250,000 | 0 | 250,000 |
| Proceeds from sale of units, net of underwriting discounts paid | - | 0 | - | - |
| Proceeds from sale of private placement units | - | 0 | - | - |
| Repayment of promissory noterelated party | - | 0 | - | - |
| Net cash provided by financing activities | - | 0 | - | - |
| Net change in cash | -158,035 | 106,124 | -56,518 | 28,315 |
| Cash beginning of period | 1,434,965 | 1,328,841 | 1,357,044 | - |
| Cash end of period | 1,276,930 | 1,434,965 | 1,328,841 | - |
Oaktree Acquisition Corp. III Life Sciences (OACCU)
Oaktree Acquisition Corp. III Life Sciences (OACCU)